155
Participants
Start Date
July 31, 2007
Primary Completion Date
September 30, 2008
Study Completion Date
September 30, 2008
omalizumab
The liquid formulation of omalizumab was packaged in a pre-filled safety syringe containing either 75 mg (0.5ml) or 150 mg (1.0 ml) of drug. The syringes were clearly marked so that the health care provider could differentiate between the 75 mg or 150 mg syringe.
Kansas City Allergy & Asthma, Overland Park
Allergy & Immunology Associates, Ltd, Scottsdale
California Allergy and Asthma Medical Group, Palmdale
Allergy Associates Medical Group, Inc,, San Diego
Bensch Research Associates, Stockton
1st Allergy and Clinical Research Center, Centennial
Innovative Research of West Florida, Inc., Largo
Georgia Pollen, Albany
Asthma and Allergy Specialists, PA, Minneapolis
: The Clinical Research Center, LLC, St Louis
Allergy, Asthma and Clinical Immunology, Brick
Asthma & Allergy Research of NJ, Inc., Mount Laurel
Nassau Chest Pysicians, PC, Massapequa
Allergy and Asthma Center of NC, PA, High Point
Allergy Center at Brookstone, Columbus
Toledo Center for Clinical Research, Sylvania
Asthma and Allergy Center, Toledo
The Corvallis Clinic, PC, Corvallis
Allergy, Asthma & Dermatology Research Center, Lake Oswego
Clinical Research Institute of Southern Oregon, PC, Medford
Allergy & Asthma Specialists, PC, Blue Bell
Asthma Allergy & Pulmonary Associates, PC, Philadelphia
AAPRI Clinical Research Institute, Providence
North Texas Institute for Clinical Trials, Fort Worth
Allergy and Asthma Associates, Houston
Clinical Trials of North Houston, Houston
Novartis Investigative Site,, Buenos Aires
Novartis Investigative Site, Buenos Aires
Novartis Investigative Site,, Corrientes
Novartis Investigative Site,, Mendoza
Novartis Investigator site, Nuremberg
Lead Sponsor
Collaborators (2)
Genentech, Inc.
INDUSTRY
Tanox
INDUSTRY
Novartis
INDUSTRY